Friday 02 May 2025
Internal Reference Number: FOI_8399
Date Request Received: 23/01/2025 00:00:00
Date Request Replied To: 21/02/2025 00:00:00
This response was sent via: By Email
Request Summary: Diffuse Large B Cell Lymphoma (BLBCL)
Request Category: Private Individuals
| Question Number 1: In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)? Of these patients, how many commenced treatment at your trust within the last 6 months? | |
| Answer To Question 1: Q1. Total patients diagnosed in last 6 months <= 5, of those total patients treated <=5 Pharmacy: <5 patients started chemo in last 6 months | |
| Question Number 2: In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments: R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) Pola-BR (polatuzumab vedotin with rituximab and bendamustine) Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone) R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate) R-IVAC (rituximab, ifosfamide, etoposide and cytarabine) R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone) (DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab) R-GemOX (rituximab, gemcitabine and oxaliplatin) Axicabtagene ciloleucel Tisagenlecleucel Epcoritamab Loncastuximab tesirine Glofitamab Any other SACT Stem cell transplant or bone marrow transplant (autologous or allogeneic) | |
| Answer To Question 2: Q2. Any other SACT <= 5, R-CHOP/R-mini-CHOP <=5 Pharmacy: RCHOP- >5 patients R-mini-CHOP- >5 patients Pola-BR- <5 patients Pola-R-CHP- 5 patients R-Gem-Ox- <5 patients Epcoritamab <5 patients Any other SACT- <5 patients All other responses for Q2 are zero | |
| Question Number 3: In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL): Axicabtagene ciloleucel (Yescarta) Tisagenlecleucel Pola-BR (polatuzumab vedotin with rituximab and bendamustine) R-GemOX (rituximab, gemcitabine and oxaliplatin) Stem cell transplant or bone marrow transplant (autologous or allogeneic) Any other treatments | |
| Answer To Question 3: Pharmacy: Pol-BR- <5 patients R-Gem-OX – <5 patients Any other SACT – <5 patients Transplants would go elsewhere so zero for response to all other questions | |
| Question Number 4: In the last 6 months, how many patients has the Trust has treated for 3rd line Diffuse Large B Cell Lymphoma (BLBCL)? | |
| Answer To Question 4: Q4. Unable to answer this as we are unable to distinguish 3rd line Diffuse Large B Cell Lymphoma (BLBCL) using a different ICD-10 diagnosis code to that used to answer Q1. Pharmacy: <5 patients | |
| Question Number 5: In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments: CAR-T Therapy (E.g. Axicabtagene ciloleucel) Stem cell transplant or bone marrow transplant (autologous or allogeneic) Any other treatment | |
| Answer To Question 5: CAR-T Therapy (E.g. Axicabtagene ciloleucel) - <5 referrals Stem cell transplant or bone marrow transplant (autologous or allogeneic) - 0 referrals Any other treatment - 0 referrals | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
